biolog
respons
modifi
evalu
mice
hepatotrop
adam
strain
punta
toro
viru
administ
intraperiton
divid
dose
signific
protect
death
confer
dose
mgkgday
given
h
previru
inocul
mgkgday
administ
h
preand
h
postviru
challeng
mg
kgday
administ
h
viru
inocul
dose
prevent
death
reduc
liver
icteru
score
serum
alanin
aminotransferas
aspart
aminotransferas
level
liver
serum
viru
titer
rel
placebo
controi
full
daili
dose
administ
h
somewhat
less
protect
mice
divid
daili
dose
start
time
initi
treatment
could
delay
late
h
viru
inocul
result
complet
protect
mortal
mgkgday
prevent
death
occur
despit
acut
natur
infect
result
death
h
placebotr
control
result
show
prophylact
therapeut
potenti
antiphleboviru
agent
interferon
induct
appear
reason
antivir
activ
model
sinc
unit
interferonml
induc
mice
h
treatment
mg
per
kg
antibodi
interferon
si
administ
shortli
treatment
nucleosid
negat
antivir
effect
phlebovirus
member
famili
bunyavirida
neg
strand
rna
virus
cash
et
al
import
pathogen
mediterranean
area
part
africa
south
america
sabin
travasso
da
rosa
et
al
repres
group
rift
valley
fever
viru
sandfli
fever
viru
consid
import
target
studi
devis
treatment
debilit
diseas
caus
major
epidem
rift
valley
fever
respons
thousand
case
infect
death
egypt
meegan
et
al
sinc
particular
strain
viru
quit
danger
man
develop
close
relat
punta
toro
viru
ptv
model
less
virul
viru
evalu
antiphleboviru
agent
antivir
agent
ribavirin
sidwel
et
al
ribamidin
sidwel
et
al
effect
treat
hepatotrop
form
diseas
mice
part
antivir
evalu
use
ptv
model
involv
studi
biolog
respons
modifi
exert
effect
cell
immun
system
agent
usual
show
antivir
activ
cell
cultur
nonimmun
cell
predominantli
use
viral
assay
nucleosid
analog
novel
biolog
respons
modifi
type
known
induc
interferon
smee
et
al
report
inhibit
broad
spectrum
rna
dna
virus
anim
infect
model
smee
et
al
smee
et
al
one
san
angelo
viru
famili
ptv
belong
california
group
bunyavirus
sather
hammon
instead
phleboviru
group
effect
prevent
death
san
angelo
viru
mice
administ
prior
within
h
viru
challeng
smee
et
al
smee
et
al
present
report
shown
effect
treatment
hepatotrop
ptv
infect
mice
interferon
induct
action
appear
respons
biolog
activ
compound
dion
provid
dri
powder
form
us
armi
medic
research
institut
infecti
diseas
via
technassoci
inc
rockvil
md
sinc
compound
rather
insolubl
salin
neutral
ph
smee
et
al
prepar
sodium
bicarbon
ph
inject
mice
bicarbon
also
serv
placebo
control
anim
studi
antibodi
interferon
purchas
lee
biomolecular
san
diego
ca
dilut
steril
water
inject
adam
strain
ptv
describ
sidwel
et
al
use
viru
origin
isol
patient
presum
infect
panama
twice
plaqu
purifi
deriv
strain
continu
passag
cell
viru
pool
made
viru
titrat
mice
specif
pathogenfre
femal
mice
weigh
gram
obtain
simonsen
laboratori
gilroy
ca
studi
larger
mice
becom
resist
lethal
infect
anim
quarantin
h
prior
use
hous
five
ten
cage
fed
wayn
laboratori
chow
tap
water
ad
libitum
dispos
micropl
contain
confluent
monolay
cell
expos
dilut
mlwell
mous
serum
sampl
presum
contain
interferon
one
day
cell
cultur
infecti
dose
vesicular
stomat
viru
ad
well
day
cell
examin
virusinduc
cytopath
effect
cpe
interferon
titer
express
maximum
dilut
supernat
fluid
inhibit
cpe
assay
develop
sidwel
huffman
uninfect
mice
weigh
prior
treatment
high
dose
mgkg
administ
halfdaili
increment
h
apart
anim
weigh
next
day
death
record
day
result
nontox
dose
select
antivir
experi
mice
inocul
subcutan
sc
lethal
dose
ptv
approxim
cell
cultur
infecti
dose
cell
evalu
sever
dose
intraperiton
ip
treatment
given
singl
inject
h
apart
variou
time
preor
postviru
inocul
studi
compound
shown
multipl
day
dose
enhanc
antivir
activ
smee
et
al
initi
mice
treat
group
mice
placebo
control
five
shaminfect
anim
treat
drug
dosag
toxic
control
uninfect
untreat
mice
serv
normal
control
toxic
normal
control
mice
maintain
area
remot
infect
mice
weigh
prior
initi
treatment
h
last
treatment
four
day
viru
inocul
infect
anim
treatment
group
placebotr
control
mice
kill
bled
liver
remov
hepat
icteru
character
discolor
liver
assign
score
normal
maxim
discolor
liver
frozen
later
assay
viru
titer
cell
describ
previous
sidwel
et
al
serum
alanin
aminotransferas
alt
aspart
aminotransferas
ast
determin
made
use
colorimetr
kit
sigma
chemic
co
st
loui
mo
anim
kill
day
held
day
viru
inocul
death
record
daili
survivor
increas
evalu
use
chi
squar
analysi
yate
correct
student
ttest
use
analyz
increas
mean
surviv
time
anim
die
day
reduct
alt
ast
reduc
ptv
titer
liver
sera
liver
score
inhibit
compar
use
rank
sum
analysi
case
valu
statist
signific
determin
compar
treat
group
respect
placebo
control
threshold
statist
signific
p
p
use
twotail
analys
sever
dose
mgkg
given
one
day
evalu
acut
toxic
mice
tabl
divid
daili
dose
mgkg
caus
death
andor
sever
weight
loss
pattern
death
somewhat
errat
dose
probabl
compound
administ
suspens
maximum
toler
dose
use
treatment
regimen
mgkg
base
upon
previou
studi
type
virus
smee
et
al
smee
et
al
prophylact
treatment
nucleosid
administ
h
viru
challeng
dose
mgkgday
significantli
effect
reduc
mortal
fig
ia
wherea
mgkg
inact
fig
seen
surviv
data
mice
treat
h
rel
viru
inocul
use
regimen
compound
effect
dose
mgkg
provid
nearli
complet
protect
otherwis
lethal
infect
diseas
paramet
group
mice
present
tabl
treatment
start
h
liver
icteru
score
alt
ast
valu
liver
serum
viru
titer
substanti
reduc
mgkg
likewis
paramet
reduc
mice
treat
nucleosid
start
h
use
dose
low
mgkg
gener
dose
significantli
reduc
diseas
paramet
reduc
mortal
addit
antivir
effect
observ
liver
score
mgkg
h
treatment
mgkg
h
treatment
ast
valu
liver
viru
titer
mgkg
h
treatment
correl
increas
surviv
treatment
initi
viru
inocul
h
dose
mgkgday
highli
effect
prevent
death
compar
placebo
control
fig
perform
determin
treatment
could
given
even
later
infect
treatment
administ
h
viru
challeng
also
effect
mgkg
dose
fig
overal
infect
latter
experi
somewhat
less
sever
placebo
control
live
compar
earlier
studi
effect
diseas
paramet
therapeut
treatment
regimen
present
tabl
inhibit
paramet
nucleosid
larg
correl
surviv
data
dose
mgkg
h
treatment
markedli
suppress
diseas
paramet
mgkg
decreas
liver
score
ast
valu
liver
viru
titer
statist
signific
dose
mgkg
h
treatment
significantli
reduc
diseas
paramet
mgkg
paramet
liver
score
significantli
reduc
previous
report
divideddaili
dose
effect
singl
dose
type
viru
infect
smee
et
al
smee
et
al
experi
conduct
determin
effect
singl
treatment
regimen
would
ptv
infect
follow
mortal
result
survivorstot
achiev
singl
daili
treatment
administ
h
viru
challeng
mgkg
mgkg
mgkg
mgkg
placebo
compar
twice
daili
treatment
fig
surviv
achiev
mgkg
mice
placebo
control
die
signific
reduct
liver
score
alt
ast
valu
liver
serum
viru
titer
evid
mgkg
singl
treatment
studi
data
shown
combin
result
demonstr
divid
daili
treatment
regimen
effect
lower
mgkg
higher
mgkg
dose
singl
treatment
regimen
previous
report
induc
ifn
swiss
webster
mice
smee
et
al
ascertain
whether
cytokin
induc
mice
anim
treat
compound
sera
collect
ifn
analysi
vari
time
fig
dose
mgkg
given
singl
inject
induc
unit
interferon
per
ml
h
administr
ifn
level
declin
steadili
h
determin
protect
role
ifn
ptv
infect
treat
mice
receiv
antibodi
ifn
xl
tabl
mice
receiv
mgkg
surviv
rate
wherea
anim
receiv
nucleosid
plu
antiifn
die
result
indic
major
role
ifn
antiptv
activ
effect
ptv
infect
whether
administ
prophylact
therapeut
efficaci
greatest
treatment
initi
h
viru
challeng
impress
treatment
begun
late
h
also
effect
albeit
high
dose
previou
studi
indic
anim
show
sign
diseas
h
sidwel
et
al
mice
dead
h
minimum
effect
dose
tv
infect
mgkg
maximum
toler
dose
inject
mice
mgkg
indic
therapeut
index
maximum
toler
dose
divid
minimum
effect
dose
approxim
antivir
agent
found
effect
semliki
forest
banzi
encephalomyocard
virus
administ
divid
daili
dose
rather
fulldaili
inject
smee
et
al
smee
et
al
also
found
case
ptv
infect
singl
treatment
mgkg
less
activ
lower
dose
suggest
much
compound
led
less
immun
activ
divid
dose
show
good
respons
dose
low
mgkg
ptv
mode
action
compound
ptv
investig
ifn
induct
appear
key
factor
antiptv
activ
level
ifn
induc
mice
persist
similar
ifn
induct
swiss
webster
mice
smee
et
al
antibodi
ifn
x
negat
protect
effect
work
perform
semliki
forest
viru
smee
et
al
establish
vivo
antivir
activ
nucleosid
could
also
elimin
treatment
mice
antiinterferon
antibodi
report
natur
killer
cell
induct
nucleosid
appear
signific
protect
factor
import
note
ifn
induc
bropirimin
wierenga
also
activ
punta
toro
viru
infect
vivo
sidwel
et
al
manuscript
submit
pifat
smith
shown
murin
ptv
infect
highli
sensit
ifn
although
studi
conduct
use
sever
day
treatment
previou
work
viru
infect
show
daili
treatment
increas
compound
efficaci
smee
et
al
like
relat
fact
hyporespons
occur
ifn
induc
follow
repeat
daili
administr
gies
kirchner
stringfellow
stringfellow
et
al
addit
certain
viru
infect
shown
creat
state
hyporespons
ifn
induc
host
effect
overcom
treatment
anim
prostaglandin
stringfellow
sinc
activ
h
viru
challeng
ptv
may
induc
hyporespons
state
mice
virus
point
requir
investig
previous
evalu
san
angelo
bunyavim
smee
et
al
smee
et
al
famili
virus
ptv
thu
comparison
antivir
activ
two
viru
model
warrant
activ
nucleosid
san
angelo
viru
observ
dose
low
mgkgday
given
h
similar
condit
effect
mgkg
ptv
efficaci
ptv
achiev
mgkg
start
treatment
h
howev
anoth
studi
shown
moder
antivir
activ
san
angelo
viru
mgkg
dose
evalu
administ
late
h
viru
inocul
differ
result
may
reflect
model
virus
replic
san
angelo
viru
replic
high
titer
mice
lead
enceph
death
smee
et
al
wherea
adam
strain
ptv
primarili
hepatotrop
sidwel
et
al
infect
caus
enceph
virus
appar
difficult
treat
viru
enter
brain
earli
time
point
viru
inocul
determin
stringfellow
colleagu
b
use
two
differ
ifn
induc
encephalomyocard
emc
viru
mice
effect
ifn
associ
immunomodul
appar
affect
brain
degre
necessari
shut
viru
replic
relat
work
perform
emc
viru
abil
delay
death
correl
suppress
viru
replic
viscer
organ
tissu
contribut
delay
viru
replic
brain
smee
et
al
result
indic
effect
treatment
ptv
infect
mice
result
compound
possibl
candid
followup
studi
model
relat
virus
rift
valley
fever
viru
role
ifn
induc
agent
treat
seriou
bunyaviru
infect
deserv
explor
